BiotechTube
Home/Nippon Shinyaku/President and Representative Director
PA

President and Representative Director

Chief Executive Officer

Nippon Shinyaku

Therapeutic Areas

Neuromuscular DisordersHematologyMetabolic DiseasesOncology

Nippon Shinyaku Pipeline

DrugIndicationPhase
Viltolarsen (Viltepso)Duchenne Muscular Dystrophy (Exon 53)Approved
NS-089/NCNP-02Duchenne Muscular Dystrophy (Exon 44)Phase 1/2
Lusutrombopag (Mulpleta)Thrombocytopenia in chronic liver diseaseApproved
Fostamatinib (TAVALISSE)Chronic Immune Thrombocytopenia (ITP)Approved
NS-580/NM-8074Paroxysmal Nocturnal Hemoglobinuria (PNH)Phase 2